Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era • Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs • Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain

Publisher Name :
Date: 01-Sep-2016
No. of pages: 135
This report is available at 15% Discount till 31st Jan 2017. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chronic Pain (2016) are definite steps taken by FDA in last two years for creating “Abuse Deterrent Era” in a short span to stop opioid abuse and reversing opioid epidemic in USA.  There were around 18,893deaths involving prescription of opioids in the United States in 2014 which was up 16% from 2013 as per NCHS (National Center for Health Statistics).

Around +6 plus extended release abuse deterrent formulations with Abuse deterrent (AD) labels are approved in last two years (Xtampza ER, MorphaBond ER, Hysingla ER, Embeda ER, Targiniq ER, Oxaydo) and are expected to provide improvements over existing formulations for abuse deterrent purpose.  But they have some limitation for restricting abuse mainly through oral intake- swallowing a number of intact tablets or capsules. Despite, Extended release (ER) Abuse Deterrent Formulations partly control Opioids abuse  (through nasal or injection routes), ER opioids has high potential of abuse, its AD formulation add significant value to create “Abuse Deterrent Era” in the coming time.

Around 20 plus Abuse Deterrent Formulations of opioids are in the pipeline and most of them are ER formulations which use different AD tech platform to make its ADF.  Amongst these pipeline ADF drugs, 6 are of Hydrocodone, 8 are of Morphine and 6 are of Oxycodone based ADF formulations.  

New NCEs targeting Opioids receptor are in pipeline which reduces Opioids abuse by its MoA (slow rate of entry in Brain) and may have potential to deal with reducing opioid abuse through restricting oral intake in coming years.  

US Opioids market is of $8b in size and of which extended release formulations contribute 50%.  ADF ER formulations and its generic versions & New NCEs targeting Opioid receptor will drive the growth of opioid market in US and Europe in coming years.

In this report, we have discussed a number of novel delivery technologies employed in the formulating abuse deterrent product, technologies employed in enhancing patient compliances, emerging novel mechanisms and late stage pipeline drugs in the management of pain.

Late stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923,…) and Novel technologies targeting formulation change in old generic drugs (ORB-201, OX-51, ARX-04,CL-108, once daily Pregabalin..) for  pain management has potential to reduce opioids use in future to treat pain. While TRKA receptor antagonist, NAV1.7 sodium channel modulator inhibitor and angiotension II antagonist are few new MoA which has promising drug in clinical development for moderate to severe pain management.

Companies mentioned:


  • AbbVie

  • AcelRx pharma

  • Acorda Therapeutics

  • Actavis

  • Acura Pharma

  • Acorda Therapeutics

  • Altus formulations

  • Alkermes

  • Algiax Pharmaceuticals

  • Amorsa Therapeutics

  • AnGes

  • AstraZeneca

  • Balerna

  • Biogen

  • BioDelivery Sciences International Inc

  • Biopharma

  • Cara Therapeutics

  • Catalent

  • Charleston

  • Celltech

  • Collegium Pharma

  • Convergence

  • Columbia Labs

  • Convatech

  • Daiichi Sankyo

  • Daewoong

  • Depomed

  • Durect

  • Egalet

  • Eli Lilly

  • Elite Pharma

  • Endo

  • Ensyce Bioscience

  • EpiCept

  • Flamel Technologies

  • Flexion Therapeutics

  • Forest

  • Glenmark

  • Grunenthal

  • GlaxoSmithKline

  • GW Pharma

  • Immune Pharmaceuticals

  • Impax Pharmaceuticals

  • Inspirion

  • Intelli Pharmaceutics

  • IRX Therapeutics

  • Johnson and Johnson

  • KemPharm

  • Kineta

  • Kunwha Pharmaceutical

  • Medallion Therapeutics

  • Mallinckrodt

  • Nektar

  • Novartis

  • Noven

  • Orbis Biosciences

  • Orexo

  • Otsuka

  • Pain Therapeutics

  • Pfizer

  • ProPharma

  • Purdue

  • Recro pharma

  • Relmada Therapeutics

  • Reckitt Benckiser pharmaceutical

  • Signature Therapeutics

  • Spinifex pharma

  • SPR Therapeutics

  • Strativa

  • Teikoku

  • Teva

  • Tesa Labtec GmpH

  • Trevena Inc

  • Tris Pharma

  • Valeant

  • ViroMed

  • Wooddiff Lake

  • Xenon Pharma

  • XenoPort

Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era • Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs • Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain

Table of Contents

1. Executive Summary
a. ER formulation of Opioids- An initial target for pipeline Abuse deterrent drugs & a high priority by Regulators?
b. Late stage pipeline drugs and new MoA – which has potential to reduce Opioid use in moderate pain?
c. New FDA guidelines for Oral solid abuse deterrent generic formulations - A kick start of generic cycle for ADF formulations?
d. Key pipeline ER abuse deterrent  drugs, its ROA, tech platform etc
e. Possible implications of rescheduling Hydrocodone from CIII to CII on Opioids market & ADF development.

2. Management of Pain
Introduction
Classification of Pain (Type and Intensity)
Treatment of chronic pain – current approach
Market Size of pain and current therapeutic options (acute, chronic pain and neuropathic pain)
Unmet medical need and market opportunities in overall  Pain management
Overview of Marketed drugs for moderate to severe pain and neuropathic pain
Limitations of non-opioids drugs and overview of marketed drugs
Non-steroidal Anti-inflammatory Drugs (NSAID) – Mechanism of action
Necessity for non-opiate treatment –Drug abuse deterrent and tolerance
Opioid Abuse deterrent Epidemic- A Whistle Blower for FDA to take Stringent Action and start of abuse deterrent  Era
ER opioids vs. IR opioids- Abuse deterrent potential

3. FDA Schedule for controlled substances and advantage of Schedule III over II
Hydrocodone rescheduling to Class II –
o Prescription trend post rescheduling
Advantage to other Opiates  & advantage to ER ADF opioids to grow due to rescheduling

4. FDA Perspective on Abuse deterrent  formulations (Opioids)
FDA perspective on Abuse deterrent Opioids- Observations from early experience with Abuse deterrent  formulation development.
FDA view of the Evolution of the Abuse deterrent  Opioid market
Tools FDA Intends to use to move the market toward its goal
ADF Labeling – Importance and  advantage for reimbursement,  REMS need
Our view on FDA guidelines for Abuse deterrent  Formulation developments
Our view on FDA guidelines for Generic Abuse deterrent  Formulation developments

5. Approved  Abuse deterrent  Formulations by FDA - Development , label claim, Technology and  current prescription trend
Common Manufacturing approach for making ADF formulation
Abuse deterrent  drugs approval from FDA in 2014- its Technology platform and current prescription trend in US
Abuse deterrent  approval from FDA in 2015- its Technology platform and current prescription trend in US
Recently approved ER Formulation of Patent expired molecules for pain management
Nucynta ER
Gralise
Horizant

6. Abuse Deterrent  Technology Platforms employed in marketed drugs and pipeline
a. AVERSION
b. IMPEDE
c. NEXAFED
d. LIMITX  
e. DETERx
f. PODRAS
g. IntelliPaste
h. nPODDDS
i. INTAC
j. ORADUR
k. Implantable pump for intrathecal delivery
l. OPTIGEL Lock
m. Small molecule delivery
n. Bio-MD-prodrugs platform
o. Ligand activated Therapy (LAT)
p. NOBUSE
q. EGALET
r. ABUSOLVE
s. Inspirion delivery Technologies
t. Intellitab Technology
u. Trigger lock platform –Micropump
v. Proprietary / OraGuard Technology
w. Pain Therapeutics
x. Fenrock
y. Smart Patch PNS system
z. ALO-02/Troxyca ER
aa.  BeadTek and INTELLITAB technology
bb. Acuform Technology
cc.  OROS Technology
dd. Resistec Technology
ee. SENTRYBOND Technology

7. Pipeline analysis of Novel Technologies and new mechanisms in Pain management

Novel Technologies-
a. Multi-day formulation of Tramadol
b. Bio-MD Platform
c. Orexo- Sublingual technology
d. Fentanyl based therapy formulation modification (micro and nano tab)
e. Acorda Therapeutics
f. Bilayered oral formulation- Charleston lab
g. ZilrettaTM  
h. Steroidal intraarticular injection
i. Intrathecal drug delivery system
j. Oromucosal delivery

New mechanisms in Pain management
a. Angiotension II antagonist
b. Anti-NGF
c. Ligand Activate Therapy
d. Nav1.  7 inhibitor
e. GPCR –Dimer Screen Technology
f. CB agonist
g. Kappa Receptor agonists
h. TrkA receptor antagonist
i. MAP kinase inhibitor
j. Opioid alternatives (dexmedetomidine)
k. Peptide Therapeutics (conopeptide)
l. TRPV1 antagonist
m. Gene therapy
n. Others

8. Late stage pipeline developments in neuropathic pain
a. Cebranopadol (oral, once daily, Grunenthal/ Depomed, PhIII, chronic pain)-A potential threat to abuse deterrent  formulations
b.  Mirogabalin- Key MOA diff vs. Lyrica, Pros & Cons analysis based on reported PhII data
c. CL-108
d. Hydromorphone
e. Convergence/ biogen Idec- CNV-2197944
f. Convergence/ biogen Idec- CNV-1014802
g. Sativex
h. Once daily pregabalin
i. Topical clonidine gel
j. Topical ketamine and amitraline
k. Amorsa therapeutics
l. Pregabalin CR
m. Eladur
n. GRC-17536
o. DWP05195
p. AVP-123
q. Algiax Pharmaceuticals

Appendix – I FDA Guidelines for the development of abuse Deterrent Formulations
Types of Abuse deterrent  formulation as per current guidance
Pre market studies
Post market studies
Labeling Recommendations

Appendix- II General Principles for Evaluating the Abuse deterrent Generic Solid Oral Opioid Drug Products
Need for regulatory filing and other key requirements
Route of Abuse deterrent
Comparative in Vitro Studies
Other Consideration
Data Analysis
Additional

List of Tables

Table-1(A):  Key pipeline ER Abuse Deterrent Drugs, its ROA, techplatform
Table-1(B): Key pipeline ER Abuse Deterrent Drugs, its ROA, techplatform
Table-1(C): Key pipeline ER Abuse Deterrent Drugs, its ROA, techplatform
Table-1(D): Key pipeline ER Abuse Deterrent Drugs, its ROA, techplatform
Table-2: Non-Injectable Opioid Pain TRx+share-US
Table-3: Classification Based on Intensity of Pain 2013-2014
Table-4: Marketed Fentanyl Dosage Forms (Us): Transdermal Patches, Buccal And Sublingual Tablets And Films For Pain Relief
Table-5: Commonly Used Opioids for Pain Management
Table-6: Marketed Drugs for Neuropathic Pain
Table-7: Drug Enforcement Authority (DEA) Controlled Substances Schedule Criteria
Table-8: Summary of Controlled Substances Act requirements
Table-9: Overview of pivotal studies conducted in the ALO-02 development program
Table-10: Benefits of Sublingual Microtablets vs.  IV morphine Patient Controlled Analgesia
Table-11: Marketed formulation of Oromucosal product
Table-12: Microgabalin –WW ongoing key clinical trials

List of Charts

Chart -1: Classification of Pain
Chart-2: Pain is multi-factorial
Chart-3: Pain Relief ladder-WHO
Chart-4: Neuropathic Pain market size and projection through 2020
Chart-5: Medicine spending in 2020 US$ by geography, product type and disease area
Chart-6: Specialty Medicines and Leading therapy areas in 2020
Chart-7: Number of Death from Prescription drugs
Chart-8: Number of Death from Heroin
Chart-9: Hydrocodone prescription volume has noticeably declined since up-scheduling
Chart-10: Total opioid market TRx and sales growth
Chart-11:  Recent long acting opioids TRx launches
Chart-12: NUCYNTA ER prescription trend-us post launch in June 2015
Chart-13: Abuse Deterrent pipeline in development-Acura pharma
Chart-14: DETERx Multiparticulate system
Chart-15: Design element of DETERx as used in Xtampza
Chart-16: Pipeline of Collegium Pharma
Chart-17: Pipeline of Intellipharmaceuticals
Chart-18: Abuse Deterrent Technology platform of Elite Pharmaceuticals
Chart-18(a): Abuse Deterrent Technology platform- One Bead System
Chart-18 (b): Abuse Deterrent Technology platform- Two Bead System
Chart-19: Guardian Technology combines abuse deterrent- features with a precision zero-order profile
Chart-20: Egalet product pipeline using GuardianTM Technology
Chart-21: Egalet’s guardian technology as used in ARYMO and Egalet-002
Chart-22: OraguardTM Manufacturing process used for Vantrela ER
Chart-23: Diagram of the cross-section of an ALO-02 pellet
Chart-24: Zohydro ER’s BeadTek technology-PEO Gels in liquids
Chart-25: Exalgo’s OROS Delivery technology- Deigned for ER not ADF
Chart-26: Stratum Tech platform- Orbis Bioscience
Chart-27:  Tramadol in Vitro Pharmacokinetic
Chart-28: PF614: Prodrug of Oxycodone (ER Oxycodone)
Chart-29: Pipeline of Enysce Bioscince
Chart-30: ZilrettaTM  cilical phase study for pain
Chart-31: Biodelivery science International BEMA technology
Chart-32: Product in pipeline utilizing BEMA technology
Chart-33: Advance in Orodispersible film for drug delivery
Chart-34: Cara therapeutics drug development
Chart-35: Cebranopadol overview
Chart-36: Cebranopadol MOA- Uniquely differentiate
Chart-37: Cebranopadol phase II clinical trial summary
Chart-37 (a): Cebranopadol phase II clinical trial summary
Chart-37 (b): Cebranopadol phase II clinical trial summary
Chart-38: Cebranopadol reduced Abuse Deterrent potential
Chart-39: Daiichi sankyo (Efficacy result of mirogabalin vs. Lyrica/Pregabalin)
Chart-40: A flow chart depicting a tier-based approach to evaluating the extractability of  Opioid from an intact product for ingestion

  • Global Morphine Sulfate Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 07-Dec-2016        Price: US 3480 Onwards        Pages: 114
    "Morphine sulfate is an opioid agonist indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. Morphine sulfate occurs as white, feathery, silky crystals; cubical masses of crystal; or white crystalline powder. It is soluble in water and slightly soluble in alcohol, but is practically insoluble in chloroform or ether. In addition to analgesia, the widely diverse effects of morphine sulfate include drowsiness, changes i......
  • Global Methadone Hydrochloride Market Research Report 2016
    Published: 05-Dec-2016        Price: US 2900 Onwards        Pages: 100
    Notes: Production, means the output of Methadone Hydrochloride Revenue, means the sales value of Methadone Hydrochloride This report studies Methadone Hydrochloride in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Eli Lilly - Sanofi Aventis - Roxane Laboratories - Ma......
  • Global Opioids Sales Market Report 2016
    Published: 29-Nov-2016        Price: US 4000 Onwards        Pages: 103
    Notes: Sales, means the sales volume of Opioids Revenue, means the sales value of Opioids This report studies sales (consumption) of Opioids in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Sanofi-aventis - Johnson & Johnson - Teva pharmaceuticals - Purdue Pharma - Pfizer......
  • Global Tramadol Market Research Report 2016
    Published: 25-Nov-2016        Price: US 2900 Onwards        Pages: 118
    Notes: Production, means the output of Tramadol Revenue, means the sales value of Tramadol This report studies Tramadol in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - Grnenthal GmbH - Mundipharma - Hexal AG - Labopharm - Pliva Pharma - Nippon Shinyaku......
  • Musculoskeletal Pain-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Musculoskeletal Pain-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Musculoskeletal Pain. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, a......
  • Myalgia-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Myalgia-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Myalgia. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, pat......
  • Non Malignant pain-Pipeline Insights, 2016
    Published: 01-Nov-2016        Price: US 1250 Onwards        Pages: 60
    DelveInsight's, " Non Malignant pain-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the Non Malignant pain. The DelveInsight'sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acqui......
  • Acute Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Acute Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Acute Pain Report is to understand the market and pipeline status of the drugs around the Acute Pain to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipel......
  • Fibromyalgia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Nov-2016        Price: US 2000 Onwards        Pages: 100
    DelveInsight's Report, "Fibromyalgia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Fibromyalgia Report is to understand the market and pipeline status of the drugs around the Fibromyalgia to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs